These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36879300)

  • 21. Targeting alpha-synuclein for the treatment of Parkinson's disease.
    Rohn TT
    CNS Neurol Disord Drug Targets; 2012 Mar; 11(2):174-9. PubMed ID: 22483285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rising to the Challenges of Clinical Trial Improvement in Parkinson's Disease.
    Mathur S; DeWitte S; Robledo I; Isaacs T; Stamford J
    J Parkinsons Dis; 2015; 5(2):263-8. PubMed ID: 25720445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of Passive Immunotherapies for Synucleinopathies.
    Bergström AL; Kallunki P; Fog K
    Mov Disord; 2016 Feb; 31(2):203-13. PubMed ID: 26704735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease.
    Török N; Majláth Z; Szalárdy L; Vécsei L
    Expert Opin Investig Drugs; 2016 Nov; 25(11):1281-1294. PubMed ID: 27677932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autosomal dominant Parkinson's disease and the route to new therapies.
    Morris HR
    Expert Rev Neurother; 2007 Jun; 7(6):649-56. PubMed ID: 17563248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new avenue for treating Parkinson's disease targeted at aggrephagy modulation and neuroinflammation: Insights from in vitro and animal studies.
    Tikhonova MA
    EBioMedicine; 2020 Jan; 51():102575. PubMed ID: 31901571
    [No Abstract]   [Full Text] [Related]  

  • 27. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations.
    Lang AE; Espay AJ
    Mov Disord; 2018 May; 33(5):660-677. PubMed ID: 29644751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
    Oertel W; Schulz JB
    J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy for Parkinson's disease: a developing therapeutic strategy.
    Bradbury J
    Drug Discov Today; 2005 Aug; 10(16):1075-6. PubMed ID: 16182188
    [No Abstract]   [Full Text] [Related]  

  • 30. Treating Parkinson's Disease with Antibodies: Previous Studies and Future Directions.
    Castonguay AM; Gravel C; Lévesque M
    J Parkinsons Dis; 2021; 11(1):71-92. PubMed ID: 33104039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Challenges to Informed Consent in First-In-Human Trials Involving Novel Treatments: A Case Study of Parkinson's Disease.
    Hug K; Johansson M
    J Parkinsons Dis; 2017; 7(4):695-702. PubMed ID: 29103049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human gene therapy approaches for the treatment of Parkinson's disease: An overview of current and completed clinical trials.
    Hitti FL; Yang AI; Gonzalez-Alegre P; Baltuch GH
    Parkinsonism Relat Disord; 2019 Sep; 66():16-24. PubMed ID: 31324556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Promising disease-modifying therapies for Parkinson's disease.
    Dawson VL; Dawson TM
    Sci Transl Med; 2019 Nov; 11(520):. PubMed ID: 31776289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease.
    Schneider SA; Alcalay RN
    J Neurol; 2020 Mar; 267(3):860-869. PubMed ID: 31974807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting α-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson's disease.
    Haque ME; Akther M; Azam S; Kim IS; Lin Y; Lee YH; Choi DK
    Br J Pharmacol; 2022 Jan; 179(1):23-45. PubMed ID: 34528272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy.
    Nimmo JT; Verma A; Dodart JC; Wang CY; Savistchenko J; Melki R; Carare RO; Nicoll JAR
    Alzheimers Res Ther; 2020 Nov; 12(1):159. PubMed ID: 33256825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy for Parkinson's disease.
    Schwab AD; Thurston MJ; Machhi J; Olson KE; Namminga KL; Gendelman HE; Mosley RL
    Neurobiol Dis; 2020 Apr; 137():104760. PubMed ID: 31978602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clues to Reshaping Anti-α-Synuclein Immunotherapy in Early Parkinson's Disease Patients.
    Palermo G; Ceravolo R
    Mov Disord; 2023 Feb; 38(2):196-197. PubMed ID: 36519627
    [No Abstract]   [Full Text] [Related]  

  • 39. Controlled trial of physiotherapy and occupational therapy for Parkinson's disease.
    Br Med J (Clin Res Ed); 1981 Jun; 282(6280):1969-70. PubMed ID: 6786690
    [No Abstract]   [Full Text] [Related]  

  • 40. Look to the future.
    Dean E
    Nurs Stand; 2012 Aug 8-14; 26(49):18-9. PubMed ID: 22930955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.